Targeting a disrupted circadian regulator to treat advanced prostate cancer
Targeting aberrant circadian regulator in advanced prostate cancer
This study is looking at how a specific protein called Rev-erbα affects advanced prostate cancer that doesn't respond to usual treatments, and it will test a new way to block this protein to see if it can help slow down the cancer and improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10993125 on NIH RePORTER |
What this research studies
This research investigates the role of a circadian rhythm regulator, Rev-erbα, in advanced prostate cancer, particularly in cases resistant to current therapies. The study aims to understand how this regulator contributes to tumor growth and survival in metastatic castration-resistant prostate cancer (mCRPC). By using small molecule antagonists to inhibit Rev-erbα, the research seeks to determine the effectiveness and safety of this approach in treating aggressive forms of prostate cancer. Patients may be monitored for changes in tumor behavior and response to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those with metastatic castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer that is resistant to existing therapies.
How similar studies have performed: Previous research has shown promise in targeting circadian regulators in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Chen, Hongwu — University of California at Davis
- Study coordinator: Chen, Hongwu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.